DRG International, Inc. Hepcidin 25 (Bioactive) HS Presented at Ash Annual Meeting 2015

Springfield, New Jersey, USA (December 2015) — DRG International, Inc. was proud to be a featured participant at ASH 2015, held in Orlando, FL from December 5 – 7, 2015! DRG International, Inc. showcased an expansive collection of its most cutting-edge products to the hematology community gathered at the ASH Annual Meeting including our:

NEW Hepcidin 25 (bioactive) HS Assay
The gold standard in Hepcidin Measurement

Now Available on our DRG:HYBRiD.XL, a fully automated continuous access analyzer for Immunoassay and Clinical Chemistry as well as in the classic ELISA format
The optimized High Sensitive Hepcidin 25 assay includes several new features, such as:
Better Sensitivity (dilution possible down to 0.153 ng/ml)
All reagents and standards ready to use
Incubation steps at room temperature
No assay buffer or shaking needed
Total assay time of 2 hours
Excellent correlation to Mass Spectrometry
DRG HYE5769 (Hybrid-XL Assay) shows good correlation to EIA5782 (Manual ELISA)

“DRG International, Inc. was proud to present at the ASH Annual Meeting for the second time,” said Dr. Cyril E. Geacintov, founder, president and CEO of DRG International. “We were exceptionally pleased with the attention our new Hepcidin 25 (bioactive) HS ELISA received, including a poster presentation entitled ‘Iron Age or New Age: Ironing out the Diagnosis of Anaemia of Inflammation from Iron Deficiency Anaemia’ by Mrs. Nicola Svenson.”

Please see a link to Mrs. Svenson’s poster here. The DRG Hepcidin 25 (bioactive) HS ELISA kit was also used in Dr. I. Papassotiriou’s paper entitled “Assessment of Serum Bioactive Hepcidin-25, Soluble Transferrin Receptor and Their Ratio in Predialysis Patients: Correlation with the Response to Intravenous Ferric Carboxymaltose Administration.” Dr. Papassotiriou is a PhD at the Aghia Sophia Children’s Hospital in Athens, Greece.

DRG International, Inc. founded in 1970, is a multinational specialty medical equipment and diagnostics manufacturer and distributor with successful operations in over 110 countries.

DRG supplies an extensive line of immunodiagnostic products including fertility and pregnancy tests, endocrinology/diabetes, saliva hormone diagnostics, tumor markers, infectious diseases, immunology/hematology, thyroid function panels, cardiovascular assays as well as therapeutic and toxicology screening products. To obtain more information about the DRG group of companies and complete product line, please visit our website at: www.drg-international.com.

L to R: Mr. Michael Martini, DRG Sales & Marketing Director; Dr. Cyril E. Geacintov, Founder, Owner, & CEO of DRG International, Inc.; Mrs. Nicola Svenson, Dr. Dorine Swinkels, Mrs. Elke G. Geacintov, DRG Executive Vice President; and Dr. Ian Cushman, DRG Laboratory & R&D Director at the DRG International, Inc. Booth.

[starbox]